"FDA Investigates Claims of Hair Loss and Suicidal Thoughts Linked to Diabetes, Weight Loss Medications"
The FDA is investigating reports of hair loss and suicidal thoughts among users of GLP-1 receptor agonists, a class of drugs used for diabetes and weight loss, including brands like Ozempic, Mounjaro, and Wegovy. While these side effects have been reported to the FDA's Adverse Event Reporting System, the agency has not yet established a causal relationship between the drugs and the risks. The FDA continues to monitor drug safety post-approval and may take actions such as updating labels or implementing risk strategies if necessary. Novo Nordisk, a manufacturer of these drugs, has stated their commitment to patient safety and ongoing collaboration with the FDA.
